Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

How BioVaxys' DPX platform creates anti-cancer immune response

Discover BioVaxys’ innovative DPX™ platform, a cutting-edge lipid-based delivery system transforming immunotherapy. This video explores how the company’s proprietary technology encapsulates diverse bioactive molecules, enhancing and sustai...

Buzz on the Bullboards: Investor caution impacts market activity

The TSX began the week on a high note, buoyed by strength in the financial and industrial sectors. However, by Tuesday, the market had slipped into the red, as investor caution took hold ahead of the upcoming U.S. inflation data. Luckily for investors, things rebounded si...

Buzz on the Bullboards: Whose stocks sizzle during summer holidays?

As we get through the summer holiday season, the typically calmer market environment presents a prime opportunity for investors to evaluate their portfolios and consider new investments. The TSX continues to offer a variety of promising stocks, particularly in energ...

NervGen: Are amazing human trial results leaking out?

“We are very excited! We are very, very excited!” So says Dr. Monica Perez, who is running the first human trial for a potential new wonder drug being developed by a tiny but well-financed life sciences start-up, NervGen Pharma Corp. ...

Buzz on the Bullboards: 3 stocks breaking the silence of a quiet June

“Sell in May and go away” is a theme investors and stock traders know well, and during this quieter month of June ahead of summer, some public Canadian companies have been engaging in serious business. This week, we saw the TSX hit a one-month ...

Minnesota helium project well positioned to help alleviate global shortage

By Marc Farrington In February this year, Pulsar Helium Inc (Pulsar) ( TSXV:PLSR ) announced extraordinarily high helium concentrations of up to 13.8% from its Jetstream No. 1 appraisal well drilled at its Topaz project in Minnesota. This has positioned Topaz as th...

Buzz on the Bullboards: Who is shining through the market slump?

The market story this week has been less impressive on both sides of the border than what we saw in the week where February turned to March. Recent losses and flatline trading have negated Wall Street’s previous record-setting run where major U.S. indices ...

Medicus Pharma advances cancer treatment towards phase II trial

The following is a transcription of the above video, and The Market Herald Canada has edited it for clarity . Our next company is Medicus Pharma Ltd. (TSXV:MDCX) , headquartered in Philadelphia, Pennsylvania. The company is a publicly traded clinical stage, multi-st...

Clinical research and tools to address mental health

Our next company is Numinus Wellness Inc. (TSX:NUMI) . Numinus is using the power of psychedelic medicine to make great strides in addressing serious mental health issues. It recently announced its fiscal year 2024 results, which showed strong growth in its busines...

Buzz on the Bullboards: Markets underperforming, or is the best yet to come?

So, the “September rally” didn’t really pan out as many indices hit lows not seen in months, but at least interest rates were kept firm for now, so that is some good news, right? Investors have been worried about the possibility o...
1 2 3 4 5 6 7 8 9 10 ...